Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 08/14 05:36:28 pm
77.5 EUR   +1.28%
08/10UCB : Transparency notification BlackRock, Inc.
PU
08/10UCB : Threshold crossings
CO
08/08UCB : Transparency notifications BlackRock, Inc.
PU
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
08/06/2018 08/07/2018 08/08/2018 08/09/2018 08/14/2018 Date
75.48(c) 75.9(c) 75.76(c) 76.52(c) 77.5(c) Last
330 333 348 710 301 914 380 321 330 705 Volume
+0.64% +0.56% -0.18% +1.00% +1.28% Change
More quotes
Financials (EUR)
Sales 2018 4 564 M
EBIT 2018 1 122 M
Net income 2018 764 M
Finance 2018 75,5 M
Yield 2018 1,64%
Sales 2019 4 724 M
EBIT 2019 1 170 M
Net income 2019 841 M
Finance 2019 657 M
Yield 2019 1,71%
P/E ratio 2018 18,74
P/E ratio 2019 17,30
EV / Sales2018 3,24x
EV / Sales2019 3,01x
Capitalization 14 884 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.The company was founded by Emmanuel Janssen on January 18, 1928 and is... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
08/10UCB : Transparency notification BlackRock, Inc.
PU
08/10UCB : Threshold crossings
CO
08/09UCB : "Method And System For Predicting Optimal Epilepsy Treatment Regimes" in P..
AQ
08/08UCB : Transparency notifications BlackRock, Inc.
PU
08/08UCB : Threshold crossings
CO
08/03UCB : Transparency notifications BlackRock, Inc.
PU
08/03UCB : Threshold crossings
CO
07/26UCB : S.A. - Transparency notifications BlackRock, Inc
AQ
07/26UCB : Half-year results
CO
07/24UCB : Transparency notifications BlackRock, Inc.
PU
More news
Sector news : Pharmaceuticals - NEC
08/14MONSANTO ROUNDUP APPEAL HAS UPHILL C : legal experts
RE
08/14CSL : Annual Net Profit Rises, Slightly Beats Guidance
DJ
08/14Billionaire Investor David Einhorn Hit In Monsanto Ruling --Update
DJ
08/14DAVID EINHORN : Billionaire Investor David Einhorn Hit In Monsanto Ruling
DJ
08/14TSX advances as oil prices boost energy stocks
RE
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on UCB 
UCB - 05/10
The comeback of an upward trend can be anticipated
BUY
UCB - 2017
After the accumulation, an upward acceleration ?
BUY
More Strategies
Latest Tweets
08/13"The Get Brown" at UCB uses sketch to goof on the comics' dual identities and..
2
08/08UCB : Transparency notifications BlackRock, Inc.  
08/05“It’s like that scene from Home Alone, except instead of cardboard cutouts, i..
1
08/03UCB : Transparency notifications BlackRock, Inc.  
07/27$UCB S.A. UCB Benefits From Label Expansion in Immunology and Epilepsy; Main.. 
More tweets
Qtime:48
News from SeekingAlpha
08/14YOUR DAILY PHARMA SCOOP : Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA.. 
08/13FDA accepts UCB's marketing application for midazolam nasal spray for seizure.. 
07/26UCB S.A. ADR 2018 Q2 - Results - Earnings Call Slides 
07/13Amgen resubmits U.S. marketing application for osteoporosis med Evenity 
06/01EMA advisory group backs expanded use for UCB's Briviact 
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Average target price 69,6 €
Spread / Average Target -9,1%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB15.62%16 965
JOHNSON & JOHNSON-6.42%350 770
PFIZER13.00%239 423
NOVARTIS-0.87%209 596
ROCHE HOLDING LTD.-3.39%207 317
MERCK AND COMPANY17.42%175 715